Moderna IPO
Moderna is a biotechnology company that develops messenger RNA therapeutics and vaccines to create new medicines for infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. The company gained global prominence for developing one of the first COVID-19 vaccines.
What We Know
Moderna went public in December 2018, trading on NASDAQ under the ticker MRNA. The company's IPO raised $604 million, making it one of the largest biotech IPOs at the time. Moderna's stock price surged dramatically during the COVID-19 pandemic as its mRNA vaccine became a cornerstone of global vaccination efforts. The company has continued to expand its mRNA platform beyond COVID-19 vaccines into other therapeutic areas and maintains a robust pipeline of mRNA-based treatments.
Frequently Asked Questions
Has Moderna had an IPO?
Yes, Moderna completed its IPO in December 2018 and trades publicly on NASDAQ under the ticker MRNA. The company has been publicly traded for over five years.
When is the Moderna IPO date?
Moderna already completed its IPO in December 2018. The company is currently publicly traded and does not need another IPO.
How can I buy Moderna stock?
You can buy Moderna stock through any brokerage account using the ticker symbol MRNA on NASDAQ. The stock is widely available to retail investors during regular trading hours.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts